{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-27",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 3
    }
  },
  "results": [
    {
      "discontinued_date": "04/28/2023",
      "update_type": "New",
      "initial_posting_date": "04/28/2023",
      "change_date": "04/28/2023",
      "package_ndc": "0069-4370-71",
      "generic_name": "Prazosin Hydrochloride Capsule",
      "contact_info": "800-533-4535",
      "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023",
      "update_date": "04/28/2023",
      "therapeutic_category": [
        "Cardiovascular"
      ],
      "dosage_form": "Capsule",
      "presentation": "Minipress, Capsule, 2 mg (NDC 0069-4370-71)",
      "company_name": "Pfizer Inc.",
      "status": "To Be Discontinued"
    }
  ]
}